Ranitidine or sucralfate do not prevent stress ulcer in intensive care patients

Ranitidine and sucralfate are widely used to prevent gastrointestinal bleeding in patients in intensive care. Several recommendations suggest this prophylaxis, but the Food and Drugs Administration (FDA) and the European Medicines Evaluation Agency (EMEA) have not given their approval. The meta-analysis by Messori et al (p 1103) shows that ranitidine does not prevent gastrointestinal bleeding, and data for sucralfate are insufficient to conclude anything on its effectiveness. Ranitidine was found to increase the risk of pneumonia under certain circumstances. Further trials are needed, but their design poses the problem of whether placebo can be given to control groups.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials
A Messori, S Trippoli, M Vaiani, M Gorini, and A Corrado
BMJ 2000 321: 1103. [Abstract] [Full Text] [PDF]




Access jobs at BMJ Careers
Whats new online at Student 

BMJ